US Tariff: This Indian pharma gaint exposed to headline risk
New Delhi: The imposition of a 100 per cent tariff by the US on imports of branded and patented pharmaceutical products starting October 1 may not significantly hurt Indian drug makers, with Sun Pharma being exposed to some headline risk but with limited earnings impact,...











































